53.89
+0.52(+0.97%)
Currency In USD
| Previous Close | 53.37 |
| Open | 54.02 |
| Day High | 54.95 |
| Day Low | 52.35 |
| 52-Week High | 68.86 |
| 52-Week Low | 25.6 |
| Volume | 371,851 |
| Average Volume | 352,148 |
| Market Cap | 1.86B |
| PE | -13.61 |
| EPS | -3.96 |
| Moving Average 50 Days | 57.14 |
| Moving Average 200 Days | 51.66 |
| Change | 0.52 |
If you invested $1000 in Disc Medicine, Inc. (IRON) since IPO date, it would be worth $523.2 as of March 12, 2025 at a share price of $53.89. Whereas If you bought $1000 worth of Disc Medicine, Inc. (IRON) shares 3 years ago, it would be worth $3,641.22 as of March 12, 2025 at a share price of $53.89.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Jan 23, 2025 2:35 AM GMT
WATERTOWN, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from s
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Jan 21, 2025 9:01 PM GMT
WATERTOWN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from s
Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission
GlobeNewswire Inc.
Jan 21, 2025 12:45 PM GMT
Pursuing accelerated approval for bitopertin in EPP with protoporphyrin IX (PPIX) reduction as the surrogate endpointPlanning to submit NDA under accelerated approval pathway in H2 2025 based on existing clinical data, including results from BEACON a